Veracyte, Inc. (NASDAQ:VCYT) – William Blair issued their Q4 2018 EPS estimates for shares of Veracyte in a report issued on Tuesday. William Blair analyst A. Murphy anticipates that the biotechnology company will earn ($0.13) per share for the quarter.

Other equities research analysts also recently issued reports about the company. Janney Montgomery Scott restated a “buy” rating and issued a $15.00 price target on shares of Veracyte in a report on Wednesday, June 28th. Cantor Fitzgerald set a $13.00 price target on Veracyte and gave the stock a “buy” rating in a report on Thursday, May 18th. BTIG Research restated a “buy” rating and issued a $13.00 price target on shares of Veracyte in a report on Thursday, August 31st. Zacks Investment Research upgraded Veracyte from a “hold” rating to a “buy” rating and set a $9.25 price target for the company in a report on Friday, August 4th. Finally, BidaskClub upgraded Veracyte from a “sell” rating to a “hold” rating in a report on Monday, July 31st. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $12.45.

TRADEMARK VIOLATION NOTICE: This article was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US and international trademark and copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/09/07/veracyte-inc-vcyt-forecasted-to-earn-q4-2018-earnings-of-0-13-per-share.html.

Veracyte (VCYT) traded down 2.92% during trading on Thursday, hitting $8.30. The company had a trading volume of 114,119 shares. The company’s market capitalization is $281.31 million. Veracyte has a 12-month low of $5.82 and a 12-month high of $9.71. The firm has a 50-day moving average of $8.11 and a 200 day moving average of $8.27.

Veracyte (NASDAQ:VCYT) last released its earnings results on Monday, July 31st. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.03. Veracyte had a negative return on equity of 53.58% and a negative net margin of 35.64%. The firm had revenue of $18.40 million for the quarter, compared to analyst estimates of $18.32 million. During the same period in the previous year, the company earned ($0.40) earnings per share. Veracyte’s revenue was up 25.2% compared to the same quarter last year.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Nationwide Fund Advisors boosted its position in Veracyte by 31.9% during the first quarter. Nationwide Fund Advisors now owns 11,327 shares of the biotechnology company’s stock valued at $104,000 after purchasing an additional 2,739 shares during the last quarter. SG Americas Securities LLC acquired a new position in Veracyte during the second quarter valued at approximately $103,000. Eagle Global Advisors LLC acquired a new position in Veracyte during the first quarter valued at approximately $119,000. William Marsh Rice University acquired a new position in Veracyte during the first quarter valued at approximately $127,000. Finally, Bank of Montreal Can acquired a new position in Veracyte during the first quarter valued at approximately $138,000. 65.67% of the stock is owned by hedge funds and other institutional investors.

In other news, Director Evan/ Fa Jones sold 20,000 shares of the company’s stock in a transaction dated Wednesday, August 23rd. The stock was sold at an average price of $7.92, for a total transaction of $158,400.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold 82,500 shares of company stock valued at $649,325 over the last ninety days. 13.40% of the stock is owned by insiders.

Veracyte Company Profile

Veracyte, Inc is a genomic diagnostics company. The Company uses genomic technology to resolve diagnostic ambiguity. It targets diseases in which patients undergo invasive diagnostic procedures. Its products combine genomic technology, clinical science and machine learning. The Company commercializes over three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis.

Earnings History and Estimates for Veracyte (NASDAQ:VCYT)

Receive News & Ratings for Veracyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte Inc. and related companies with MarketBeat.com's FREE daily email newsletter.